XERS
Xeris Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XERS
Xeris Biopharma Holdings, Inc.
A biopharmaceutical company that develops therapies for endocrinology, neurology, and gastroenterology
180 N. LaSalle Street, Suite 1300, Chicago, Illinois 60607
--
Xeris Biopharma Holdings, Inc., was incorporated in 2005 under the laws of the State of Delaware. The company is committed to building an innovative, self-sustaining, growth-oriented biopharmaceutical company dedicated to improving the lives of patients by developing and commercializing clinically meaningful products in a range of therapies. The company is uniquely positioned to achieve this with three commercial products and proprietary formulation science (XeriSol and XeriJect) to build partnerships and enhance product candidates.
Earnings Call
Q1/2025
Estimate EPS-0.04
Actual EPS-0.06
Estimate Revenue57.61M
Actual Revenue60.12M
Xeris Biopharma's 2025 Q1: Contradictions Unveiled in Infrastructure Expansion, Profitability, and XP-8121 Development
May 19,2025 08:48
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.03
Actual EPS-0.01
Estimate Revenue64.58M
Actual Revenue71.54M
Xeris Biopharma's Q2 2025: Navigating Contradictions in Recorlev Growth, Gvoke Strategy, and Margin Outlook
Aug 07,2025 08:03
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
XERS has released its 2025 Q3 earnings. EPS was reported at 0, versus the expected 0, meeting expectations. The chart below visualizes how XERS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XERS has released its 2025 Q3 earnings report, with revenue of 74.38M, reflecting a YoY change of 37.06%, and net profit of 621.00K, showing a YoY change of 103.95%. The Sankey diagram below clearly presents XERS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
